ACAD
Acadia Pharmaceuticals
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
ACAD Profile
Acadia Pharmaceuticals Inc.
A biopharmaceutical company that developing medicines for central nervous system disorders
Biological Technology
Invalid Date
05/27/2004
NASDAQ Stock Exchange
653
12-31
Common stock
12830 El Camino Real, Suite 400, San Diego, California 92130
--
Founded in Vermont in 1993, Acadia Pharmaceuticals Inc., is a biopharmaceutical company focused on the development and commercialization of innovative micromolecular drugs to address unmet medical needs in neurological and central nervous system diseases. The company has a series of product candidates, led by pimavanserin, which is in the third stage of development for the treatment of Parkinson's disease. The company has successfully completed the pivotal Phase 3 trial and the company plans to submit a new drug application to the US Food and Drug Administration by the end of 2014. Pimavanserin is in the second phase of Alzheimer's treatment development and has successfully completed the second phase of trials as a synergistic treatment for Alzheimer's disease. The company's products also include a chronic pain and glaucoma clinical-stage program with Allergan, as well as two advanced clinical programs for the treatment of Parkinson's disease and other neurological diseases. All of the company's candidate products and projects come from internal research and development.